The Matched Group was defined as T-SCLC patients receiving subtype-specific therapies: LUAD-like subtypes treated with EGFR-TKI or Bevacizumab based therapy, or Non-LUAD-like subtypes treated with platinum-based chemotherapy ± immunotherapy. This evidence concerns the gene EGFR and small cell lung carcinoma.